Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID-19 pandemic.


Journal

Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007

Informations de publication

Date de publication:
01 2022
Historique:
received: 13 09 2021
accepted: 15 09 2021
pubmed: 7 10 2021
medline: 5 1 2022
entrez: 6 10 2021
Statut: ppublish

Résumé

The declaration of Coronavirus disease 2019 (COVID-19) as a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 required rapid implementation of early investigations to inform appropriate national and global public health actions. The suite of existing pandemic preparedness generic epidemiological early investigation protocols was rapidly adapted for COVID-19, branded the 'UNITY studies' and promoted globally for the implementation of standardized and quality studies. Ten protocols were developed investigating household (HH) transmission, the first few cases (FFX), population seroprevalence (SEROPREV), health facilities transmission (n = 2), vaccine effectiveness (n = 2), pregnancy outcomes and transmission, school transmission, and surface contamination. Implementation was supported by WHO and its partners globally, with emphasis to support building surveillance and research capacities in low- and middle-income countries (LMIC). WHO generic protocols were rapidly developed and published on the WHO website, 5/10 protocols within the first 3 months of the response. As of 30 June 2021, 172 investigations were implemented by 97 countries, of which 62 (64%) were LMIC. The majority of countries implemented population seroprevalence (71 countries) and first few cases/household transmission (37 countries) studies. The widespread adoption of UNITY protocols across all WHO regions indicates that they addressed subnational and national needs to support local public health decision-making to prevent and control the pandemic.

Sections du résumé

BACKGROUND
The declaration of Coronavirus disease 2019 (COVID-19) as a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 required rapid implementation of early investigations to inform appropriate national and global public health actions.
METHODS
The suite of existing pandemic preparedness generic epidemiological early investigation protocols was rapidly adapted for COVID-19, branded the 'UNITY studies' and promoted globally for the implementation of standardized and quality studies. Ten protocols were developed investigating household (HH) transmission, the first few cases (FFX), population seroprevalence (SEROPREV), health facilities transmission (n = 2), vaccine effectiveness (n = 2), pregnancy outcomes and transmission, school transmission, and surface contamination. Implementation was supported by WHO and its partners globally, with emphasis to support building surveillance and research capacities in low- and middle-income countries (LMIC).
RESULTS
WHO generic protocols were rapidly developed and published on the WHO website, 5/10 protocols within the first 3 months of the response. As of 30 June 2021, 172 investigations were implemented by 97 countries, of which 62 (64%) were LMIC. The majority of countries implemented population seroprevalence (71 countries) and first few cases/household transmission (37 countries) studies.
CONCLUSION
The widespread adoption of UNITY protocols across all WHO regions indicates that they addressed subnational and national needs to support local public health decision-making to prevent and control the pandemic.

Identifiants

pubmed: 34611986
doi: 10.1111/irv.12915
pmc: PMC8652791
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7-13

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : COVID-19 Solidarity Response Fund for WHO
Organisme : German Federal Ministry of Health (BMG) COVID-19 Research and Development for WHO

Informations de copyright

© 2021 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.

Références

Lancet Glob Health. 2016 Dec;4(12):e911-e912
pubmed: 27815145
J Clin Virol. 2020 Aug;129:104540
pubmed: 32652475
Lancet. 2021 Apr 10;397(10282):1347-1348
pubmed: 33770519
Influenza Other Respir Viruses. 2022 Jan;16(1):7-13
pubmed: 34611986

Auteurs

Isabel Bergeri (I)

WHO Health Emergencies Programme, World Health Organization Headquarters, Geneva, Switzerland.

Hannah C Lewis (HC)

WHO Health Emergencies Programme, World Health Organization Headquarters, Geneva, Switzerland.

Lorenzo Subissi (L)

WHO Health Emergencies Programme, World Health Organization Headquarters, Geneva, Switzerland.

Anthony Nardone (A)

WHO Health Emergencies Programme, World Health Organization Headquarters, Geneva, Switzerland.
Epidemiology Departement, Epiconcept, Paris, France.

Marta Valenciano (M)

WHO Health Emergencies Programme, World Health Organization Headquarters, Geneva, Switzerland.
Epidemiology Departement, Epiconcept, Paris, France.

Brianna Cheng (B)

WHO Health Emergencies Programme, World Health Organization Headquarters, Geneva, Switzerland.

Ketevan Glonti (K)

WHO Health Emergencies Programme, World Health Organization Headquarters, Geneva, Switzerland.

Bridget Williams (B)

WHO Health Emergencies Programme, World Health Organization Headquarters, Geneva, Switzerland.

Ibukun-Oluwa Omolade Abejirinde (IO)

WHO Health Emergencies Programme, World Health Organization Headquarters, Geneva, Switzerland.

Alice Simniceanu (A)

WHO Health Emergencies Programme, World Health Organization Headquarters, Geneva, Switzerland.

Alessandro Cassini (A)

WHO Health Emergencies Programme, World Health Organization Headquarters, Geneva, Switzerland.

Rebecca Grant (R)

WHO Health Emergencies Programme, World Health Organization Headquarters, Geneva, Switzerland.

Angel Rodriguez (A)

Pan American Health Organization, Washington, D.C., USA.

Andrea Vicari (A)

Pan American Health Organization, Washington, D.C., USA.

Lubna Al Ariqi (L)

World Health Organization for the Eastern Mediterranean, Cairo, Egypt.

Tasnim Azim (T)

Regional Office for South-East Asia, World Health Organization, New Delhi, India.

Pushpa Ranjan Wijesinghe (PR)

Regional Office for South-East Asia, World Health Organization, New Delhi, India.

Soatiana Cathycia Rajatonirina (SC)

Regional Office for Africa, World Health Organization, Brazzaville, Republic of the Congo.

Joseph Chukwudi Okeibunor (JC)

Regional Office for Africa, World Health Organization, Brazzaville, Republic of the Congo.

Linh-Vi Le (LV)

Regional Office for the Western Pacific, World Health Organization, Manila, Philippines.

Mark Katz (M)

Regional Office for Europe, World Health Organization, Copenhagen, Denmark.

Aisling Vaughan (A)

Regional Office for Europe, World Health Organization, Copenhagen, Denmark.

Pernille Jorgensen (P)

Regional Office for Europe, World Health Organization, Copenhagen, Denmark.

Gudrun Freidl (G)

Regional Office for Europe, World Health Organization, Copenhagen, Denmark.

Richard Pebody (R)

Regional Office for Europe, World Health Organization, Copenhagen, Denmark.

Maria D Van Kerkhove (MD)

WHO Health Emergencies Programme, World Health Organization Headquarters, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH